Altre lingue NervGen Pharma Corp.

Azioni

NGEN

CA64082X2032

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:59:59 24/04/2024			Variaz. 5gg	Var. 1 gen.
2,09 ^CAD	+1,46%		+5,56%	-22,59%

17/04	NervGen riporta una perdita netta di 0,38 dollari per azione per l'esercizio 2023, e fornisce un aggiornamento delle operazioni	MT
17/04	NervGen Pharma Corp. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17/04
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17/04
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09/04
NervGen Pharma Closes C$23 Million Bought Deal Financing	28/03
NervGen Completes $23 Million Bought Deal Financing	28/03
Canadian Investment Regulatory Organization Trade Resumption - NGEN	21/03
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	21/03
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	21/03
Canadian Investment Regulatory Organization Trading Halt - NGEN	21/03
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21/02
NervGen Pharma Grants Stock Options	20/02
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15/02
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15/02
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	09/11
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	08/11
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/10/23
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/10/23
Nervgen Pharma Appoints John Ruffolo to Board of Directors	18/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NervGen Pharma Corp.

Azioni

NGEN

CA64082X2032

Altre lingue

Filtri